接受血管紧张素系统抑制剂治疗的复发性胶质母细胞瘤患者使用贝伐单抗治疗的结果
Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors.
作者信息
Johansen Maria Dinche, Urup Thomas, Holst Camilla Bjørnbak, Christensen Ib Jarle, Grunnet Kirsten, Lassen Ulrik, Friis Søren, Poulsen Hans Skovgaard
机构信息
a Department of Radiation Biology, Department of Oncology , The Finsen Center , Rigshospitalet, Copenhagen , Denmark.
b Department of Gastroenterology , Hvidovre Hospital , Hvidovre , Denmark.
出版信息
Cancer Invest. 2018;36(9-10):512-519. doi: 10.1080/07357907.2018.1544639.
PURPOSE
Antihypertensive therapy may improve bevacizumab efficacy in cancer patients. We examined efficacy and toxicity of angiotensin system inhibitors (ASI) and other antihypertensive drugs in bevacizumab treated recurrent glioblastoma patients.
METHODS
We retrospectively combined a national prescription registry with a clinical database with recurrent glioblastoma patients (n = 243).
RESULTS
Patients who initiated ASI after bevacizumab (n = 26) showed a tendency towards improved progression-free survival and overall survival (OS) with hazard rate (HR) reductions (HR = 0.70 and HR = 0.79, respectively). Calcium antagonists during bevacizumab therapy significantly improved OS (HR = 0.57).
CONCLUSIONS
Overall the study supports a potential beneficial effect of antihypertensive treatment on prognosis of bevacizumab treated glioblastoma patients.
目的
抗高血压治疗可能会提高贝伐单抗在癌症患者中的疗效。我们研究了血管紧张素系统抑制剂（ASI）和其他抗高血压药物在接受贝伐单抗治疗的复发性胶质母细胞瘤患者中的疗效和毒性。
方法
我们回顾性地将一个国家处方登记处与一个复发性胶质母细胞瘤患者的临床数据库（n = 243）相结合。
结果
在使用贝伐单抗后开始使用ASI的患者（n = 26）显示出无进展生存期和总生存期（OS）改善的趋势，风险率（HR）降低（分别为HR = 0.70和HR = 0.79）。在贝伐单抗治疗期间使用钙拮抗剂可显著改善OS（HR = 0.57）。
结论
总体而言，该研究支持抗高血压治疗对接受贝伐单抗治疗的胶质母细胞瘤患者预后可能具有有益影响。
Zotero 插件